TNF and inflammatory bowel disease: Biotechnological monoclonal antibodies—the first targeted therapies licensed for the treatment of steroid-dependent or -refractory IBD—act by blocking a single immunologic target, such as specific cytokines (TNF-α or IL-23) or gut-tropic integrins (e.g., α4β7).